Ascendis health news

Here are some recent news articles and updates related to Ascendis Pharma, a biopharmaceutical company focused on developing treatments for rare and orphan diseases:

Recent News

  1. Ascendis Pharma Announces Positive Phase 3 Results for TransCon PTH for Hypoparathyroidism (February 2023)

Ascendis Pharma announced positive results from its Phase 3 clinical trial of TransCon PTH, a long-acting parathyroid hormone (PTH) treatment for hypoparathyroidism. The trial met its primary endpoint, demonstrating significant improvements in calcium levels and bone mineral density.

  1. Ascendis Pharma Receives FDA Orphan Drug Designation for TransCon CNP for Congenital Muscular Dystrophy (January 2023)

The US Food and Drug Administration (FDA) granted orphan drug designation to Ascendis Pharma's TransCon CNP, a long-acting C-type natriuretic peptide (CNP) treatment for congenital muscular dystrophy. This designation provides incentives for the development of treatments for rare diseases.

  1. Ascendis Pharma Presents Data on TransCon PTH at the 2022 American Society for Bone and Mineral Research Annual Meeting (October 2022)

Ascendis Pharma presented data from its Phase 3 clinical trial of TransCon PTH at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. The data demonstrated significant improvements in bone mineral density and calcium levels in patients with hypoparathyroidism.

Pipeline Updates

  1. TransCon PTH: Ascendis Pharma is developing TransCon PTH for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by low levels of parathyroid hormone. The company is currently conducting a Phase 3 clinical trial to evaluate the safety and efficacy of TransCon PTH.

  2. TransCon CNP: Ascendis Pharma is developing TransCon CNP for the treatment of congenital muscular dystrophy, a group of rare genetic disorders characterized by muscle weakness and wasting. The company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of TransCon CNP.

Company Updates

  1. Ascendis Pharma Appoints New Chief Medical Officer (September 2022)

Ascendis Pharma appointed Dr. David M. Goldstein as its new Chief Medical Officer. Dr. Goldstein has over 20 years of experience in the biotech industry and has led clinical development programs for several rare disease treatments.

  1. Ascendis Pharma Expands Manufacturing Capabilities (June 2022)

Ascendis Pharma expanded its manufacturing capabilities by investing in new equipment and facilities. The company plans to use these capabilities to support the commercial launch of its products, including TransCon PTH.

I hope this information is helpful!